Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The combination of vancomycin, gentamicin, and levofloxacin refers to a specific antibiotic regimen investigated by the Indiana University School of Medicine in a pharmacokinetic study (NCT00126178). This research focused on determining the extent of intradialytic drug removal for these three agents in patients undergoing short-daily hemodialysis, a schedule that differs from conventional thrice-weekly treatments. Vancomycin is a glycopeptide antibiotic that inhibits bacterial cell wall synthesis; gentamicin is an aminoglycoside that interferes with protein synthesis by binding to the 30S ribosomal subunit; and levofloxacin is a fluoroquinolone that inhibits DNA replication by targeting DNA gyrase and topoisomerase IV. The study aimed to develop precise dosing guidelines to ensure that therapeutic levels are maintained in this specific patient population to effectively treat bacterial infections while minimizing the risk of toxicity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on vancomycin + gentamicin + levofloxacin.